

Androgenic Agents TESTOPEL (testosterone pellets) S0189 Prior Authorization Request

Prior Authorization Request Medicare Part B Form

Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

□ Standard Request– (72 Hours)				☐ Urgent Request (standard time frame could place the member's life, health or ability in serious jeopardy)					
Date Requested									
	Requestor Clinic name: _						/ Fax		
MEMBER INFORMATION									
*Name:*II				D#:*DOB:					
PRESCRIBER INFORMATION									
*Na	me:	🗆	NP □D	O □NP □PA	*Phone	e:	 		
*Address:				*Fax:					
DISPENSING PROVIDER / ADMINISTRATION INFORMATION									
*Na	me:			Phone:					
*Add	dress:			Fax:					
PROCEDURE / PRODUCT INFORMATION									
нс	PC Code	Name of Drug	Dos	se (Wt: _	kg Ht:)	Frequency	End Date if known	
□ Self-administered □ Provider-administered □ Home Infusion									
☐ Chart notes attached. Other important information:									
Diagnosis: ICD10: Description:									
☐ Provider attests the diagnosis provided is an FDA-Approved indication for this drug									
CLINICAL INFORMATION									
 □ New Start or Initial Request: (Clinical documentation required for all requests) □ Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria. If not, please provide clinical rationale for formulary exception: 									
☐ Continuation Requests: (Clinical documentation required for all requests) ☐ Patient had an <u>adequate response</u> or <u>significant improvement</u> while on this medication. If not, please provide clinical rationale for continuing this medication:									
ACKNOWLEDGEMENT									
Request By (Signature Required):									



Prior Authorization Group - Androgenic Agents PA

Drug Name(s):

TESTOPEL TESTOSTERONE

Criteria for approval of Prior Authorization Drug:

- 1. Prescribed for an approved FDA diagnosis (as listed below):
- 2. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
- If the member meets all these criteria, they may be approved by the Plan for the requested drug.
- Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria:

N/A

Prescriber Restrictions:

N/A

Coverage Duration:

Approval will be for 12 months

FDA Indications:

TESTOPEL

- Replacement therapy in congenital or acquired conditions associated with a deficiency or absence of endogenous testosterone
 - Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy
 - Hypogonadotropic hypogonadism (congenital or acquired) gonadotropic LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma or radiation

Off-Label Uses:

TESTOPEL

- Female-to-male transsexual Gender dysphoria
- Osteoporosis, Male
- Weight gain

Age Restrictions:

Can be used in adolescents: Female-to-male transsexual - Gender dysphoria

Other Clinical Considerations:

TESTOPEL – Contraindications:

- Breast cancer, male
- Females who are pregnant, may become pregnant, or who are breastfeeding; known teratogen; exposure of female fetus or nursing infant to testosterone residue may result in varying degrees of virilization
- Hypersensitivity to testosterone or any component of the product
- Prostate cancer, known or suspected
- Use in women





Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/F0EAB7/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYN_C/0639FA/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Testosterone&fromInterSaltBase=true&UserMdxSearchTerm=%24userMdxSearchTerm&false=null&=null#_

